MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer

The p53 gene and MDM2 gene play critical roles in cell cycle arrest and apoptosis together. Here, we evaluated the associations of prostate cancer risk and survival with the joint effects of mdm2 and p53 polymorphisms. Totally 1,193 cases and 1,310 age frequency-matched controls were included in the study. Prostate cancer patients were followed to determine the intervals of overall survival and disease-free survival. The Pro72Arg Pro allele (homozygous and heterozygous) were significantly associated with prostate cancer risk with an odds ratio (OR) of 0.77 [95% confidence interval(CI), 0.64-0.93]. SNP309 T alleles were associated with a significantly decreased prostate cancer risk among Pro72Arg Pro alleles carriers (OR=0.79, 95% CI, 0.64-0.98). In addition, comparedwith the Pro72Arg Pro alleles and SNP309 G homozygous, patients carrying both SNP309 T alleles and Pro72Arg Arg homozygous had more favorable disease-free survival (hazard ratio [HR] = 0.59, 95% CI, 0.38-0.93). Our results indicated that SNP309 and Pro72Arg polymorphisms may jointly contributeto the etiology and prognosis of prostate cancer.

• Publication year

  2015

• Venue

  OncoTarget

• Publication date

  2015-05-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.18632/oncotarget.3923PMID 26025918PMCID 5077979
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients

  2014cited by this paper
• Association of p53 codon 72 polymorphism with prostate cancer: an update meta-analysis

  2014cited by this paper
• Clarification of data for a meta-analysis: p53 codon 72 polymorphism and prostate cancer risk.

  2012cited by this paper
• MTHFR C677T polymorphism and pancreatic cancer risk: a meta-analysis.

  2012cited by this paper
• Meta-analysis of associations between the MDM2-T309G polymorphism and prostate cancer risk.

  2012cited by this paper
• TP53 codon 72 polymorphism affects accumulation of mtDNA damage in human cells

  2012cited by this paper
• Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?

  2012cited by this paper
• Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

  2011cited by this paper
• Association between p53 Pro72Arg polymorphism and prostate cancer risk: a meta-analysis

  2011cited by this paper
• MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk

  2011cited by this paper
• Association of p53 codon 72 polymorphism with prostate cancer: a meta-analysis

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• P53 Codon 72 (Arg72Pro) Polymorphism and Prostate Cancer Risk: Association between Disease Onset and Proline Genotype

  2011cited by this paper
• p53 Pro72Arg polymorphism and prostate cancer in men of African descent

  2010cited by this paper
• Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells

  2009cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Role of p53 Codon 72 Arginine Allele in Cell Survival in vitro and in the Clinical Outcome of Patients with Advanced Breast Cancer

  2008cited by this paper
• Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients

  2007cited by this paper
• Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study.

  2006cited by this paper
• Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.

  2006cited by this paper
• MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.

  2006cited by this paper
• A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells*

  2005cited by this paper
• A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

  2004cited by this paper
• p53 polymorphic variants at codon 72 exert different effects on cell cycle progression

  2004cited by this paper
• Evidence against involvement of p53 polymorphism in breast cancer predisposition

  2003cited by this paper
• Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy

  2003cited by this paper
• Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed‐backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms

  2003cited by this paper
• Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival.

  2003cited by this paper
• The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells

  2002cited by this paper
• Abnormal Expression of MDM2 in Prostate Carcinoma

  2001cited by this paper
• Assessing TP53 status in human tumours to evaluate clinical outcome

  2001cited by this paper
• Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically

  1999cited by this paper
• p53, the Cellular Gatekeeper Review for Growth and Division

  1997cited by this paper
• Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

  1993cited by this paper

• Deep Sequencing Reveals Novel Mutations in Androgen Receptor-Related Genes in Prostate Cancer

  2025cites this paper
• The inhibition effect of psoralen on prostate cancer PC3 cells via down-regulation of long non-coding RNA ENST00000510619

  2024cites this paper
• Integrated analysis identifies GABRB3 as a biomarker in prostate cancer

  2024cites this paper
• Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies

  2021cites this paper
• Association of MDM2 T309G (rs2279744) Polymorphism and Expression Changes With Risk of Prostate Cancer in the Slovak Population

  2020cites this paper
• Mutational signatures in tumours induced by high and low energy radiation in Trp53 deficient mice

  2020cites this paper
• Selected CDKN2A and MDM2 polymorphisms in oral cavity cancer.

  2020cites this paper
• Immunogenetics of prostate cancer: a still unexplored field of study.

  2018cites this paper
• Molecular Pathogenesis of Prostate Cancer

  2017cites this paper
• Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen

  2017cites this paper
• Molecular mechanisms involving prostate cancer racial disparity.

  2017cites this paper
• Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk

  2016cites this paper
• Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells.

  2016cites this paper
• Association of genetic variants with tumor HPV16 status and survival in squamous cell carcinoma of the oropharynx.

  2016cites this paper
• Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma

  2016cites this paper
• Relationships between cell cycle pathway gene polymorphisms and risk of hepatocellular carcinoma.

  2016cites this paper